ATE244729T1 - Verfahren zur identifizierung von wirkstoffen gegen hcv durch verwendung von strukturkoordinaten der hepatitis-c-virus- protease - Google Patents
Verfahren zur identifizierung von wirkstoffen gegen hcv durch verwendung von strukturkoordinaten der hepatitis-c-virus- proteaseInfo
- Publication number
- ATE244729T1 ATE244729T1 AT01101009T AT01101009T ATE244729T1 AT E244729 T1 ATE244729 T1 AT E244729T1 AT 01101009 T AT01101009 T AT 01101009T AT 01101009 T AT01101009 T AT 01101009T AT E244729 T1 ATE244729 T1 AT E244729T1
- Authority
- AT
- Austria
- Prior art keywords
- hepatitis
- virus protease
- active ingredients
- structural coordinates
- against hcv
- Prior art date
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/576—Immunoassay; Biospecific binding assay; Materials therefor for hepatitis
- G01N33/5767—Immunoassay; Biospecific binding assay; Materials therefor for hepatitis non-A, non-B hepatitis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C30—CRYSTAL GROWTH
- C30B—SINGLE-CRYSTAL GROWTH; UNIDIRECTIONAL SOLIDIFICATION OF EUTECTIC MATERIAL OR UNIDIRECTIONAL DEMIXING OF EUTECTOID MATERIAL; REFINING BY ZONE-MELTING OF MATERIAL; PRODUCTION OF A HOMOGENEOUS POLYCRYSTALLINE MATERIAL WITH DEFINED STRUCTURE; SINGLE CRYSTALS OR HOMOGENEOUS POLYCRYSTALLINE MATERIAL WITH DEFINED STRUCTURE; AFTER-TREATMENT OF SINGLE CRYSTALS OR A HOMOGENEOUS POLYCRYSTALLINE MATERIAL WITH DEFINED STRUCTURE; APPARATUS THEREFOR
- C30B29/00—Single crystals or homogeneous polycrystalline material with defined structure characterised by the material or by their shape
- C30B29/54—Organic compounds
- C30B29/58—Macromolecular compounds
-
- C—CHEMISTRY; METALLURGY
- C30—CRYSTAL GROWTH
- C30B—SINGLE-CRYSTAL GROWTH; UNIDIRECTIONAL SOLIDIFICATION OF EUTECTIC MATERIAL OR UNIDIRECTIONAL DEMIXING OF EUTECTOID MATERIAL; REFINING BY ZONE-MELTING OF MATERIAL; PRODUCTION OF A HOMOGENEOUS POLYCRYSTALLINE MATERIAL WITH DEFINED STRUCTURE; SINGLE CRYSTALS OR HOMOGENEOUS POLYCRYSTALLINE MATERIAL WITH DEFINED STRUCTURE; AFTER-TREATMENT OF SINGLE CRYSTALS OR A HOMOGENEOUS POLYCRYSTALLINE MATERIAL WITH DEFINED STRUCTURE; APPARATUS THEREFOR
- C30B7/00—Single-crystal growth from solutions using solvents which are liquid at normal temperature, e.g. aqueous solutions
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B15/00—ICT specially adapted for analysing two-dimensional or three-dimensional molecular structures, e.g. structural or functional relations or structure alignment
- G16B15/30—Drug targeting using structural data; Docking or binding prediction
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2299/00—Coordinates from 3D structures of peptides, e.g. proteins or enzymes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/24011—Flaviviridae
- C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
- C12N2770/24222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
- G01N2333/08—RNA viruses
- G01N2333/18—Togaviridae; Flaviviridae
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B15/00—ICT specially adapted for analysing two-dimensional or three-dimensional molecular structures, e.g. structural or functional relations or structure alignment
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Physics & Mathematics (AREA)
- Immunology (AREA)
- Crystallography & Structural Chemistry (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Urology & Nephrology (AREA)
- Biotechnology (AREA)
- Hematology (AREA)
- Materials Engineering (AREA)
- Metallurgy (AREA)
- Spectroscopy & Molecular Physics (AREA)
- Biomedical Technology (AREA)
- Pharmacology & Pharmacy (AREA)
- Evolutionary Biology (AREA)
- Cell Biology (AREA)
- Theoretical Computer Science (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Bioinformatics & Computational Biology (AREA)
- Food Science & Technology (AREA)
- Analytical Chemistry (AREA)
- Communicable Diseases (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Virology (AREA)
- Gastroenterology & Hepatology (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US2527496P | 1996-09-12 | 1996-09-12 | |
US08/731,336 US6153579A (en) | 1996-09-12 | 1996-10-18 | Crystallizable compositions comprising a hepatitis C virus NS3 protease domain/NS4A complex |
Publications (1)
Publication Number | Publication Date |
---|---|
ATE244729T1 true ATE244729T1 (de) | 2003-07-15 |
Family
ID=26699520
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AT97942450T ATE216400T1 (de) | 1996-09-12 | 1997-09-12 | Kristallisierbare zusammensetzungen, die einen komplex von protein-domäne ns3aus dem virus von hepatitis c und ns4a enthalten und damit bereitgestellte kristalle |
AT03015398T ATE346088T1 (de) | 1996-09-12 | 1997-09-12 | Kristallisierbare zusammensetzungen, die einen komplex von protease-domäne ns3 und ns4a aus dem hepatitis c virus enthalten, und damit bereitgestellte kristalle |
AT01101009T ATE244729T1 (de) | 1996-09-12 | 1997-09-12 | Verfahren zur identifizierung von wirkstoffen gegen hcv durch verwendung von strukturkoordinaten der hepatitis-c-virus- protease |
Family Applications Before (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AT97942450T ATE216400T1 (de) | 1996-09-12 | 1997-09-12 | Kristallisierbare zusammensetzungen, die einen komplex von protein-domäne ns3aus dem virus von hepatitis c und ns4a enthalten und damit bereitgestellte kristalle |
AT03015398T ATE346088T1 (de) | 1996-09-12 | 1997-09-12 | Kristallisierbare zusammensetzungen, die einen komplex von protease-domäne ns3 und ns4a aus dem hepatitis c virus enthalten, und damit bereitgestellte kristalle |
Country Status (13)
Country | Link |
---|---|
US (2) | US6153579A (de) |
EP (1) | EP0935609B1 (de) |
JP (1) | JP2001501602A (de) |
AT (3) | ATE216400T1 (de) |
AU (1) | AU736857B2 (de) |
CA (1) | CA2264964A1 (de) |
DE (3) | DE69736995T2 (de) |
DK (1) | DK0935609T3 (de) |
ES (2) | ES2175462T3 (de) |
HK (2) | HK1022700A1 (de) |
IL (1) | IL128826A0 (de) |
PT (2) | PT935609E (de) |
WO (1) | WO1998011134A1 (de) |
Families Citing this family (28)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP4080541B2 (ja) | 1996-10-18 | 2008-04-23 | バーテックス ファーマシューティカルズ インコーポレイテッド | セリンプロテアーゼ、特にc型肝炎ウイルスns3プロテアーゼの阻害因子 |
IL143798A0 (en) | 1999-01-08 | 2002-04-21 | Bristol Myers Squibb Co | Hepatitis c virus ns3 protease |
US6524589B1 (en) * | 1999-04-08 | 2003-02-25 | Schering Corporation | Compositions of hepatitis C virus NS3/NS4A complex and methods for crystallizing same |
JP2003511467A (ja) | 1999-10-14 | 2003-03-25 | ブリストル−マイヤーズ スクイブ カンパニー | アンドロゲンレセプターリガンド結合ドメインの結晶構造 |
US7491808B2 (en) | 2000-06-15 | 2009-02-17 | Novartis Vaccines And Diagnostics, Inc. | HCV non-structural protein mutants and uses thereof |
SV2003000617A (es) | 2000-08-31 | 2003-01-13 | Lilly Co Eli | Inhibidores de la proteasa peptidomimetica ref. x-14912m |
HUP0600776A2 (en) | 2000-11-14 | 2007-01-29 | Bristol Myers Squibb Co | A human serpin secreted from lymphoid cells lsi-01 |
AU2002303218A1 (en) | 2001-04-03 | 2002-11-11 | Bristol-Myers Squibb Company | Polynucleotide encoding a novel cysteine protease of the calpain superfamily, can-12, and variants thereof |
US20030027315A1 (en) * | 2001-09-24 | 2003-02-06 | Ada Yonath | Methods of growing crystals of free and antibiotic complexed large ribosomal subunits, and methods of rationally designing or identifying antibiotics using structure coordinate data derived from such crystals |
US20050009877A1 (en) * | 2003-05-15 | 2005-01-13 | Henry Lu | Methods of identifying HCV NS5B polymerase inhibitors and their uses |
TW201127828A (en) | 2003-09-05 | 2011-08-16 | Vertex Pharma | Inhibitors of serine proteases, particularly HCV NS3-NS4A protease |
KR20060120166A (ko) | 2003-10-27 | 2006-11-24 | 버텍스 파마슈티칼스 인코포레이티드 | Hcv ns3-ns4a 단백질분해효소 저항성 돌연변이 |
US8187874B2 (en) | 2003-10-27 | 2012-05-29 | Vertex Pharmaceuticals Incorporated | Drug discovery method |
US8399615B2 (en) | 2005-08-19 | 2013-03-19 | Vertex Pharmaceuticals Incorporated | Processes and intermediates |
AR055395A1 (es) | 2005-08-26 | 2007-08-22 | Vertex Pharma | Compuestos inhibidores de la actividad de la serina proteasa ns3-ns4a del virus de la hepatitis c |
US7964624B1 (en) | 2005-08-26 | 2011-06-21 | Vertex Pharmaceuticals Incorporated | Inhibitors of serine proteases |
US7705138B2 (en) | 2005-11-11 | 2010-04-27 | Vertex Pharmaceuticals Incorporated | Hepatitis C virus variants |
EP1951748B1 (de) | 2005-11-11 | 2013-07-24 | Vertex Pharmaceuticals, Inc. | Varianten des hepatitis-c-virus |
JP5436864B2 (ja) | 2006-02-27 | 2014-03-05 | バーテックス ファーマシューティカルズ インコーポレイテッド | Vx−950を含む共結晶体およびそれを含む医薬組成物 |
EP1993994A2 (de) * | 2006-03-16 | 2008-11-26 | Vertex Pharmceuticals Incorporated | Deuterierte hepatitis-c-protease-hemmer |
US8440443B1 (en) | 2006-05-16 | 2013-05-14 | Merck Sharp & Dohme Corp. | MEK1 polypeptides |
ES2379905T3 (es) | 2007-02-27 | 2012-05-04 | Vertex Pharmceuticals Incorporated | Co-cristales y composiciones farmacéuticas que los comprenden |
NZ579295A (en) | 2007-02-27 | 2012-03-30 | Vertex Pharma | Inhibitors of serine proteases |
CL2008002549A1 (es) | 2007-08-30 | 2010-09-03 | Vertex Pharma | Cocristal que comprende vx-950 y un formador de cocristal seleccionado de acido 3-metoxi-4hidroxibenzoico,acido 2,4-dihidroxibenzoico y acido 2,5-dihidroxibenzoico; metodo de preparacion; composicion farmaceutica que comprende el cocristal, util como agente antiviral en el tratamiento del hcv. |
US8988881B2 (en) * | 2007-12-18 | 2015-03-24 | Sandia Corporation | Heat exchanger device and method for heat removal or transfer |
US9005417B1 (en) | 2008-10-01 | 2015-04-14 | Sandia Corporation | Devices, systems, and methods for microscale isoelectric fractionation |
US9795961B1 (en) | 2010-07-08 | 2017-10-24 | National Technology & Engineering Solutions Of Sandia, Llc | Devices, systems, and methods for detecting nucleic acids using sedimentation |
WO2012118982A2 (en) | 2011-03-02 | 2012-09-07 | Sandia Corporation | Axial flow heat exchanger devices and methods for heat transfer using axial flow devices |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4833233A (en) * | 1987-08-20 | 1989-05-23 | The United States Of America As Represented By The Administrator Of The National Aeronautics And Space Administration | Human serum albumin crystals and method of preparation |
US5353236A (en) * | 1992-04-23 | 1994-10-04 | The Board Of Trustees Of The Leland Stanford University | High-resolution crystallographic modelling of a macromolecule |
US5453937A (en) * | 1993-04-28 | 1995-09-26 | Immunex Corporation | Method and system for protein modeling |
IT1272179B (it) * | 1994-02-23 | 1997-06-16 | Angeletti P Ist Richerche Bio | Metodologia per riprodurre in vitro l'attivita' proteolitica della proteasi ns3 del virus hcv. |
-
1996
- 1996-10-18 US US08/731,336 patent/US6153579A/en not_active Expired - Lifetime
-
1997
- 1997-09-12 CA CA002264964A patent/CA2264964A1/en not_active Abandoned
- 1997-09-12 DE DE69736995T patent/DE69736995T2/de not_active Expired - Lifetime
- 1997-09-12 WO PCT/US1997/016182 patent/WO1998011134A1/en active IP Right Grant
- 1997-09-12 PT PT97942450T patent/PT935609E/pt unknown
- 1997-09-12 AT AT97942450T patent/ATE216400T1/de not_active IP Right Cessation
- 1997-09-12 AT AT03015398T patent/ATE346088T1/de not_active IP Right Cessation
- 1997-09-12 PT PT01101009T patent/PT1118619E/pt unknown
- 1997-09-12 AU AU44145/97A patent/AU736857B2/en not_active Ceased
- 1997-09-12 EP EP97942450A patent/EP0935609B1/de not_active Expired - Lifetime
- 1997-09-12 DK DK97942450T patent/DK0935609T3/da active
- 1997-09-12 ES ES97942450T patent/ES2175462T3/es not_active Expired - Lifetime
- 1997-09-12 DE DE69723485T patent/DE69723485T2/de not_active Expired - Lifetime
- 1997-09-12 DE DE69712085T patent/DE69712085T2/de not_active Expired - Lifetime
- 1997-09-12 IL IL12882697A patent/IL128826A0/xx unknown
- 1997-09-12 ES ES01101009T patent/ES2202228T3/es not_active Expired - Lifetime
- 1997-09-12 AT AT01101009T patent/ATE244729T1/de not_active IP Right Cessation
- 1997-09-12 JP JP10513899A patent/JP2001501602A/ja not_active Ceased
-
1999
- 1999-02-25 US US09/257,667 patent/US6303287B1/en not_active Expired - Lifetime
-
2000
- 2000-02-17 HK HK00100944A patent/HK1022700A1/xx not_active IP Right Cessation
- 2000-02-17 HK HK01108615A patent/HK1038573A1/xx not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
EP0935609B1 (de) | 2002-04-17 |
AU736857B2 (en) | 2001-08-02 |
DE69723485D1 (de) | 2003-08-14 |
DK0935609T3 (da) | 2002-07-22 |
ES2202228T3 (es) | 2004-04-01 |
PT1118619E (pt) | 2003-11-28 |
ATE216400T1 (de) | 2002-05-15 |
EP0935609A1 (de) | 1999-08-18 |
PT935609E (pt) | 2002-09-30 |
HK1022700A1 (en) | 2000-08-18 |
DE69723485T2 (de) | 2004-05-27 |
IL128826A0 (en) | 2000-01-31 |
DE69736995D1 (de) | 2007-01-04 |
DE69736995T2 (de) | 2007-09-20 |
US6153579A (en) | 2000-11-28 |
HK1038573A1 (en) | 2002-03-22 |
DE69712085D1 (de) | 2002-05-23 |
JP2001501602A (ja) | 2001-02-06 |
US6303287B1 (en) | 2001-10-16 |
ATE346088T1 (de) | 2006-12-15 |
WO1998011134A1 (en) | 1998-03-19 |
AU4414597A (en) | 1998-04-02 |
ES2175462T3 (es) | 2002-11-16 |
DE69712085T2 (de) | 2002-11-28 |
CA2264964A1 (en) | 1998-03-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ATE244729T1 (de) | Verfahren zur identifizierung von wirkstoffen gegen hcv durch verwendung von strukturkoordinaten der hepatitis-c-virus- protease | |
ATE552340T1 (de) | Hepatitis c virus genotypsequenzen sowie ihre verwendung als behandlungs- und nachweismitteln | |
EA199900388A1 (ru) | Ингибиторы серин-протеаз, в частности ns3 протеазы вируса гепатита c (hvc) | |
IT1278077B1 (it) | Metodologia per riprodurre in vitro le attivita' di rna polimerasi rna-dipendente e di nucleotidiltransferasi terminale codificate dal | |
DK0754704T3 (da) | Syntetiske antigener til påvisning af antistoffer mod hepatitis c-virus | |
ATE500323T1 (de) | Subtilisin-variante | |
DE69637867D1 (de) | Verfahren zur Kontrollierung der Sialylierung von durch Säugetierzellkultur hergestellten Proteinen | |
ATE281647T1 (de) | Verfahren zur typisierung von hepatitis c viren und dafür zu verwendende reagenzien | |
ATE171710T1 (de) | Hcv peptidantigene und verfahren zur bestimmung von hcv | |
DE59509642D1 (de) | Verfahren zur modifizierung der stabilität von antikörpern | |
ATE260972T1 (de) | Verfahren zur aktivierung von denaturiertem protein | |
DE69013471D1 (de) | Methode zur Stabilisierung von rekombinanten Hepatitis-B-Virus-Oberflächenproteinen aus Hefe. | |
DE69334328D1 (de) | Antigene Peptide zur Gruppierung des Hepatitis-C-Virus, Kit damit und Verfahren zur Gruppierung unter Verwendung dieses Kits | |
DE3873273D1 (de) | Verfahren zur selektiven spaltung von fusionsproteinen. | |
DE59109261D1 (de) | Von proteinen des hepatitis c-virus abgeleitete polypeptide und deren verwendung | |
ATE439368T1 (de) | Schnellreifende fluoreszierende proteine und verfahren zu deren anwendung | |
RU93043621A (ru) | Способы получения гликопротеинов нсv, способ очистки, аналитический набор, способ выявления нсv, способ элиминации нсv, способ индукции иммунитета, гликопротеины, иммунореагенты | |
KR960023052A (ko) | 높은 활성을 갖는 재조합된 c형 간염바이러스 프로티애즈 및 그 프로티애즈에 대한 저해제 탐색방법 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
UEP | Publication of translation of european patent specification |
Ref document number: 1118619 Country of ref document: EP |
|
REN | Ceased due to non-payment of the annual fee |